electroCore (NASDAQ:ECOR) had its target price dropped by equities research analysts at Cantor Fitzgerald from $23.00 to $19.00 in a research report issued on Wednesday, The Fly reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price points to a potential upside of 401.32% from the company’s previous close.

Several other research firms have also weighed in on ECOR. Zacks Investment Research lowered electroCore from a “hold” rating to a “sell” rating in a report on Friday, April 26th. Noble Financial began coverage on electroCore in a report on Wednesday, May 8th. They set an “outperform” rating and a $19.00 target price on the stock. Finally, BTIG Research lowered electroCore from a “buy” rating to a “neutral” rating in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $20.25.

NASDAQ:ECOR opened at $3.79 on Wednesday. electroCore has a 12-month low of $3.72 and a 12-month high of $20.25. The firm has a market capitalization of $110.41 million and a PE ratio of -3.18.

electroCore (NASDAQ:ECOR) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.07. On average, research analysts anticipate that electroCore will post -2.05 earnings per share for the current fiscal year.

In related news, insider Joseph P. Errico sold 39,592 shares of electroCore stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $5.52, for a total value of $218,547.84. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Joseph P. Errico sold 10,408 shares of electroCore stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $6.97, for a total value of $72,543.76. The disclosure for this sale can be found here.

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of electroCore in the third quarter valued at about $3,862,000. Suffolk Capital Management LLC increased its position in electroCore by 26.6% during the fourth quarter. Suffolk Capital Management LLC now owns 40,972 shares of the company’s stock worth $256,000 after buying an additional 8,604 shares during the last quarter. Wsfs Capital Management LLC acquired a new position in electroCore during the fourth quarter worth approximately $63,000. Vanguard Group Inc acquired a new position in shares of electroCore in the third quarter valued at approximately $1,988,000. Finally, Vanguard Group Inc. acquired a new position in shares of electroCore in the third quarter valued at approximately $1,988,000. 14.09% of the stock is currently owned by institutional investors and hedge funds.

About electroCore

electroCore, Inc, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Featured Article: Candlestick

The Fly

Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.